IL2 and neoplasm: Our data demonstrated LPS‐Nb36 treatment coupled with irradiated DC/HepG2, DC/A549, or DC/MGC-803 fusion cells contributed to an enhanced release of inflammatory mediators (TNF-α, IFN-γ, and IL-2) in contrast to the DC/tumor fusion groups (p < 0.001) (Fig. 4B).